Dr. Ruoting Yang in Molecular Psychiatry on biotypes for PTSD

NanoBioFab co-founder garners industry attention

Geneva Scientist Dr. Ruoting Yang first-authored a manuscript published in Molecular Psychiatry on biotypes for post-traumatic stress disorder (PTSD), the first of their kind of any psychological disorder. Dr. Yang is a Computational Biologist, specializing in artificial intelligence, software, and biomarker research.

He is part of the PTSD Systems Biology Consortium, a network of world-renowned scientists from the Walter Reed Army Institute of Research (WRAIR), Harvard, New York University (NYU), University of California San Francisco (UCSF), Institute for Systems Biology, and Mount Sinai Hospital, who are devoted to identifying biomarkers for PTSD. In a published manuscript titled “Epigenetic biotypes of post-traumatic stress disorder in war-zone exposed veteran and active duty males,” researchers used blood tests from male, combat-exposed veterans over a period of three years to identify two distinct biotypes which had differing genetic markers.

Read more about Dr. Yang’s work on biotyping and PTSD therapeutics at https://genevausa.org/news/story/identifying-biotypes-for-post-traumatic-stress-disorder-for-the-first-time/

Dr. Yang is also the co-founder of FITCI-based Nanobiofab, along with his wife, Dr. Xiaonao Liu. NanoBioFab uses a patented nanotechnololgy platform to develop wearable, intelligent, nanotech-based healthcare and medical devices to provide accurate, real-time data using the body’s own skin vapor-print.

Find out more about their premier product, the INOSE wearable, at nanobiofab.com